New guidelines identify best treatments to help ALS patients live longer, easierOctober 13, 2009ST. PAUL, Minn. - New guidelines from the American Academy of Neurology identify the most effective treatments for amyotrophic lateral sclerosis (ALS), often called Lou Gehrig's disease. The guidelines are published in the October 13, 2009, issue of Neurology®, the medical journal of the American Academy of Neurology. "While we are waiting for a cure, people need to know that a lot can be done to make life easier and longer for people with ALS," said lead guidelines author Robert G. Miller, MD, with the Department of Neurology at California Pacific Medical Center in San Francisco and Fellow of the American Academy of Neurology. ALS is a rapidly progressive and fatal neurologic disease that attacks the nerve cells that control voluntary muscles. Eventually people with ALS are not able to stand or walk, or use their hands and arms, and they have difficulty breathing and swallowing. Most people with ALS die within three to five years from the onset of symptoms. However, about 10 percent survive for 10 or more years. According to the guidelines, the drug riluzole should be offered to people with ALS to slow the rate at which the disease progresses. Riluzole is the only drug approved by the U.S. Food and Drug Administration to treat ALS and has a modest effect on prolonging survival. The guidelines also state that life expectancy will likely increase and quality of life may increase for people with ALS who use an assisted-breathing device. Longer life expectancy is also likely for people with ALS who use a feeding tube known as a PEG tube, since nutrition plays a critical role in prolonging survival. The guidelines also recommend doctors consider offering their patients botulinum toxin B to treat sialorrhea, also known as drooling, if oral medications do not help. Moreover, doctors should consider screening their patients for behavioral or thinking problems because studies show many people with ALS have these problems. Such problems might affect some patients' willingness to accept suggested treatments. "Important treatments available for people with ALS are often not suggested by doctors and not used by patients," said Miller. "It's important that people with ALS know that more treatments are now available to ease the burden of the disease and that they should see neurologists who are aware of these new guidelines and follow them." In addition, the guidelines recommend people with ALS enroll early in a specialized multidisciplinary ALS clinic to optimize care. "Attending a multidisciplinary clinic will likely increase survival and access to treatments, and may improve quality of life," said Miller. The cause of ALS is not known, and it's not yet known why ALS strikes some people and not others. American Academy of Neurology |
|||||||||||||||||||||
| Related Amyotrophic Lateral Sclerosis Current Events and Amyotrophic Lateral Sclerosis News Articles Schizophrenia gene's role may be broader, more potent, than thought UCSF scientists studying nerve cells in fruit flies have uncovered a new function for a gene whose human equivalent may play a critical role in schizophrenia. Compound shows potential for slowing progression of ALS A chemical cousin of a drug currently used to treat sepsis dramatically slows the progression of amyotrophic lateral sclerosis, better known as ALS or Lou Gehrig's disease, in mice. Scientists encouraged by new mouse model's similarities to human ALS A new mouse model of amyotrophic lateral sclerosis (ALS) closely resembles humans with the paralyzing disorder, researchers at Washington University School of Medicine in St. Louis report. Amyotrophic lateral sclerosis may involve a form of sudden, rapid aging of the immune system Premature aging of the immune system appears to play a role in the development of amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, according to research scientists from the Maxine Dunitz Neurosurgical Institute at Cedars-Sinai Medical Center, the Weizmann Institute of Science in Israel, and Sheba Medical Center in Israel. Physician-assisted suicide does not increase severity of depression, grief among family members Unlike other forms of suicide, physician assisted death does not cause substantial regret, or a sense of rejection among surviving family members. Mechanism related to the onset of various genetic diseases revealed Researchers at the Department of Biochemistry and Molecular Biology of Universitat Autònoma de Barcelona (UAB) have revealed the process by which proteins with a tendency to cause conformational diseases such as amyotrophic lateral sclerosis, familial amyloidotic polyneuropathy, familial amyloidotic cardiomyopathy, etc. finally end up causing them. Michigan Tech Mathematicians Identify Genes Linked to Lou Gehrig's Disease Michigan Technological University researchers have linked three genes to the most common type of amyotrophic lateral sclerosis (ALS), generally known as Lou Gehrig's disease. New Jefferson study may redefine how a chronic auto-immune disease is diagnosed New research from Jefferson Hospital for Neuroscience (JHN) may redefine how Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is diagnosed. Fatal brain disease at work well before symptoms appear University of Florida scientists have discovered why a paralyzing brain disorder speeds along more rapidly in some patients than others - a finding that may finally give researchers an entry point toward an effective treatment for amyotrophic lateral sclerosis, often referred to as ALS or Lou Gehrig's disease. Nervous system may be culprit in deadly muscle disease Brain may win out over brawn as the primary cause of breathing problems in children with a severe form of muscular dystrophy known as Pompe disease. More Amyotrophic Lateral Sclerosis Current Events and Amyotrophic Lateral Sclerosis News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||